Literature DB >> 8738977

The penetration of autoantibodies into cells may induce tolerance to self by apoptosis of autoreactive lymphocytes and cause autoimmune disease by dysregulation and/or cell damage.

D Alarcón-Segovia1, L Llorente, A Ruíz-Argüelles.   

Abstract

Autoantibodies to intracellular constituents often occur naturally. This would be difficult to understand were they unable to penetrate live cells, as was once generally accepted; however, they can and in so doing may alter cell functions, cause damage and even kill cells by apoptosis. Different autoantibodies have different effects and in this paper, further to our previous report on the penetration of anti-DNA, the penetration of anti-RNP, which may be a possible cause of apoptosis, is demonstrated. Penetration of lymphocytes by autoantibodies may play a role in the causation of autoimmune disease, influencing immune regulation and causing cell damage either directly or through nucleosomal DNA release as a result of apoptosis. This, in turn, could also further promote antigen-driven production of anti-DNA. In addition, by causing apoptosis of autoreactive cell clones, natural autoantibodies could influence tolerance during development and also later in life, thus, paradoxically, helping prevent autoimmune disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8738977     DOI: 10.1006/jaut.1996.0038

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  9 in total

1.  The predestination of autoantibodies.

Authors:  D Alarcón-Segovia
Journal:  Curr Rheumatol Rep       Date:  2001-06       Impact factor: 4.592

2.  Immunophenotypic characterization of lymphoid cell infiltrates in vitiligo.

Authors:  S Sanchez-Sosa; M Aguirre-Lombardo; G Jimenez-Brito; A Ruiz-Argüelles
Journal:  Clin Exp Immunol       Date:  2013-08       Impact factor: 4.330

3.  Polyreactive anti-DNA monoclonal antibodies and a derived peptide as vectors for the intracytoplasmic and intranuclear translocation of macromolecules.

Authors:  A Avrameas; T Ternynck; F Nato; G Buttin; S Avrameas
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-12       Impact factor: 11.205

4.  IgG from patients with liver diseases inhibit mitochondrial respiration in permeabilized oxidative muscle cells: impaired function of intracellular energetic units?

Authors:  Lumme Kadaja; Kai E Kisand; Nadezhda Peet; Urmo Braun; Kaja Metsküla; Kaupo Teesalu; Riina Vibo; Kalle V Kisand; Raivo Uibo; Harald Jockusch; Enn K Seppet
Journal:  Mol Cell Biochem       Date:  2004 Jan-Feb       Impact factor: 3.396

5.  B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels.

Authors:  Mark N Lazarus; Tabitha Turner-Stokes; Konstantia-Maria Chavele; David A Isenberg; Michael R Ehrenstein
Journal:  Rheumatology (Oxford)       Date:  2012-02-15       Impact factor: 7.580

6.  Immunological evidence and regulatory potential for cell-penetrating antibodies in intravenous immunoglobulin.

Authors:  Aggeliki D Sali; Ioannis Karakasiliotis; Maria Evangelidou; Stratis Avrameas; Peggy Lymberi
Journal:  Clin Transl Immunology       Date:  2015-10-02

Review 7.  BP180 Is Critical in the Autoimmunity of Bullous Pemphigoid.

Authors:  Yale Liu; Liang Li; Yumin Xia
Journal:  Front Immunol       Date:  2017-12-08       Impact factor: 7.561

8.  Autoantibodies in Serum of Systemic Scleroderma Patients: Peptide-Based Epitope Mapping Indicates Increased Binding to Cytoplasmic Domains of CXCR3.

Authors:  Andreas Recke; Ann-Katrin Regensburger; Florian Weigold; Antje Müller; Harald Heidecke; Gabriele Marschner; Christoph M Hammers; Ralf J Ludwig; Gabriela Riemekasten
Journal:  Front Immunol       Date:  2018-03-22       Impact factor: 7.561

Review 9.  Targeted Intracellular Delivery of Antibodies: The State of the Art.

Authors:  Tatiana A Slastnikova; A V Ulasov; A A Rosenkranz; A S Sobolev
Journal:  Front Pharmacol       Date:  2018-10-24       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.